ArticleCurrent protocols2026
Integrative in silico and in vitro screening of small molecules targeting RNA.
Article in Current protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative in silico and in vitro screening of small molecules targeting RNA.Current protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Targeting structured RNA elements with small molecules has emerged as a promising yet technically challenging strategy for antiviral drug discovery. Here, we present a comprehensive and experimentally validated workflow for the integrative in silico and in vitro screening of RNA-binding small molecules. The approach is exemplified using conserved RNA elements from the SARS-CoV-2 genome, including the 5'-terminal stem-loop 1 and the programmed -1 ribosomal frameshift pseudoknot, but is broadly applicable to other structured RNAs. The workflow integrates high-resolution RNA structural ensemble generation with virtual screening (VS) and nuclear magnetic resonance (NMR)-based experimental validation. Conformational ensembles generated by fragment-assembly approaches serve as targets for docking chemically diverse fragments and lead-like libraries. Top-ranked compounds are prioritized through consensus scoring and evaluated using ligand- and RNA-observed NMR experiments to confirm binding, characterize interaction modes, and assess specificity. Such ranking allows for NMR-guided fragment optimization, which enables systematic improvement of solubility, affinity, and selectivity through iterative medicinal chemistry in the pharmaceutical pipeline. Detailed procedures are provided for library preparation, ensemble-based VS, hit validation, data interpretation, and progression toward functional assays, together with practical considerations, quality-control parameters, and troubleshooting guidance to ensure reproducibility. By combining computational and experimental strategies that select for high-specificity ligands within a unified framework, this set of protocols accelerates the discovery and optimization of RNA-targeting small molecules and provides a scalable platform for RNA-focused drug discovery. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Target and library preparation for virtual screening Basic Protocol 2: Ensemble-based virtual screening of low-molecular-weight compounds against RNA targets Basic Protocol 3: Comparative hit prioritization and selectivity filtering for RNA-binding small molecules Basic Protocol 4: Preparation of RNA samples for in vitro validation of small-molecule binding Basic Protocol 5: NMR-based in vitro screening of RNA-small molecule interactions Support Protocol: Preparation of ligand stocks and NMR-based quality control Basic Protocol 6: Characterization and prioritization of validated RNA-binding hits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.